Huadong Med Acquires ADC for Ovarian Cancer in $305 Million Agreement
October 19, 2020 at 05:17 AM EDT
Huadong Medicine in-licensed greater China rights to an antibody-drug conjugate developed by ImmunoGen in a $305 million agreement. IMGN853 (mirvetuximab soravtansine) is in a US Phase III trial for platinum-resistant ovarian cancer, with data expected in 2021. Huadong will pay $40 million upfront and up to $265 million in milestones. Its subsidiary, Hangzhou Zhongmei Huadong Pharma, will be in charge of China development. More details.... Stock Symbols: (SHZ: 000963) (NSDQ: IMGN) Share this with colleagues: // //
